ArticleThe British journal of dermatology2018
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.
Article in The British journal of dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719649 (The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial), which is not on this map. Cited by 91 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial
Who cites it
91 citing papers in PubMed, 4 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Corticosteroid-induced manic and/or psychotic symptoms: a systematic review.Frontiers in pharmacology · 2025Pooled it
- Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus.Dermatology (Basel, Switzerland) · 2024Guideline
- Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II.Frontiers in medicine · 2022Pooled it
- Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).The British journal of dermatology · 2020Pooled it
- Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study.Advances in therapy · 2026Trial
- Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.Paediatric drugs · 2023Trial
- The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis.Clinical pharmacology and therapeutics · 2021Trial
- Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.Paediatric drugs · 2021Trial
- Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.Acta dermato-venereologica · 2021Trial
- Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.The British journal of dermatology · 2021Trial
- A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Trial
- Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.American journal of clinical dermatology · 2020Trial
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.JAMA dermatology · 2020Trial
- Aqueous extract ofPharmaceutical biology · 2026Article
- Current Challenges in Atopic Dermatitis: An Italian Delphi Consensus with a Special Focus on Moderate Disease.Dermatology and therapy · 2026Article
- Atopic dermatitis is associated with herpes zoster in adults - A matched cohort study using electronic health records data in England.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Amelioration of Atopic Dermatitis by Frankincense Oil Extract Is Associated with TRPV3 Regulation and Cutaneous Inflammation Suppression.International journal of molecular sciences · 2026Article
- Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study.Dermatology and therapy · 2026Article
- Pathobiology of atopic dermatitis and association with disease severity after acute oral steroid treatment.The journal of allergy and clinical immunology. Global · 2026Article
- Calcineurin Inhibitors in Atopic Dermatitis: Balancing Tradition with Emerging Therapeutics.Medical sciences (Basel, Switzerland) · 2026Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 12 institutions in 10 countries.
Funding
Abstract
backgroundGuidelines discourage the use of systemic corticosteroids for atopic dermatitis (AD), but their use remains widespread.
objectivesTo reach consensus among an international group of AD experts on the use of systemic corticosteroids for AD.
methodsA survey consisting of statements accompanied by visual analogue scales ranging from 'strongly disagree' to 'neutral' to 'strongly agree' was distributed to the International Eczema Council (IEC). Consensus was reached in agreement on a statement if < 30% of respondents marked to the left of 'neutral' towards 'strongly disagree'.
resultsSixty of 77 (78%) IEC members participated. Consensus was reached on 12 statements, including that systemic corticosteroids should generally be avoided but can be used rarely for severe AD under certain circumstances, including a lack of other treatment options, as a bridge to other systemic therapies or phototherapy, during acute flares in need of immediate relief, in anticipation of a major life event or in the most severe cases. If used, treatment should be limited to the short term. Most respondents agreed that systemic corticosteroids should never be used in children, but consensus was not reached on that statement. The conclusions of our expert group are limited by a dearth of high-quality published evidence. If more stringent consensus criteria were applied (e.g. requiring < 20% of respondents marking towards 'strongly disagree'), consensus would have been reached on fewer statements.
conclusionsBased on expert opinion from the IEC, routine use of systemic corticosteroids for AD is generally discouraged and should be reserved for special circumstances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.